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Structured Abstract  
 
Objective There has been controversy about the results of the Women’s Health 
Initiative (WHI) and Million Women Study (MWS) and uncertainty about their 
impact on hormone therapy (HT) use.  This study documents recent trends in HT use 
in postmenopausal women in the UK. 
 
Design Between April 2001 and September 2005, 202,638 postmenopausal women 
aged 50-74 and with no history of bilateral oophorectomy, were recruited to the 
United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The 
proportion of women randomised each month who were using HT was calculated.  
The trend in HT use was assessed with reference to the publication of the WHI 
interim results (July 2002), the MWS (August 2003) and advice from the UK 
Committee on Safety of Medicines (Dec 2003).   
 
Results The median number of women recruited and randomised per month was 
3,955 (mean 3,744). The proportion of randomised women using HT between April 
2001 and June 2002 was 29%.  This was followed by a steady monthly decline and by 
February to September 2005 only 10-11% of newly recruited women were using HT. 
This trend was present in all age groups. However in current users, average duration 
of HT use remained steady at 10-11 years. 
 
Conclusions There was a steady decline in HT use in postmenopausal women at 
recruitment into UKCTOCS between April 2001 and Sept 2005.  This is likely to 
reflect general trends in the UK population and is probably related to the premature 
closure of the large HT trials and the ensuing publicity. 
 
Keywords: hormone/hormone replacement therapy; change in use; United Kingdom; 
UKCTOCS 
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Introduction 
 
In the past two decades there have been marked changes in the recommendations and 
uptake of hormone therapy (HT).  In 1990, 10% of women aged 50-64 years used 
HT.1 Following observational studies showing significant benefits in treatment of 
menopausal symptoms and reduction in the incidence of osteoporosis, cardiovascular 
disease, Alzheimer’s disease, depression, stroke and colon cancer,2-5 this figure rose 
steadily to 30% in 1995.1 
 
In the late 1990s, large randomised controlled trials in the US (Women’s Health 
Initiative, WHI) and observational studies in the UK (Million Women Study, MWS) 
were instituted to confirm the findings of the smaller studies.  The estrogen and 
progestogen arm of the WHI study was terminated prematurely in May 2002 due to 
the reported increase in the risk of breast cancer, coronary heart disease, stroke and 
pulmonary embolism. These risks were felt to outweigh any benefits from reduced 
risks of osteoporotic fractures and colorectal carcinoma.6 In the UK, this led to media 
headlines - “HRT does more harm than good” (Daily Mail, 20th September 2002).  In 
August 2003, publication of results from the MWS added further support to the view 
that the long term use of HT is associated with an increase in the risk of incident and 
fatal breast cancer.7 The UK-based WISDOM trial (Women's International Study on 
long Duration Oestrogen after Menopause) which was similar in design to the US-
based WHI, closed in October 2002 following review of data from the WHI by the 
Medical Research Council.8 In December 2003, the HABITS trial addressing the issue 
of whether HT use was safe in women who had a previous history of breast cancer 
was prematurely stopped because of the increased risk of recurrence of breast cancer 
in menopausal women on HT.9 Soon after, the UK Committee on Safety of Medicines 
(CSM) issued guidance that HT use be restricted to treatment of symptoms and that 
the smallest dose be used for shortest duration.  Finally in February 2004, the estrogen 
only arm of the WHI initiative was stopped as it showed no effect on cardiovascular 
disease, increased risk of stroke and a lower risk of breast cancer that was not 
statistically significant.10,11 Interpretation of these studies have been highly 
controversial and there is uncertainty about the implications of these findings for 
women using HT.12 
 
This analysis was undertaken to document trends in HT use in postmenopausal 
women in the UK between 2001 to 2005 by examining HT use at recruitment in a 
large clinical trial, the United Kingdom Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS). 
 
Methods 
 
UKCTOCS is a randomised controlled trial of ovarian cancer screening in the general 
population aimed at assessing the impact of early detection on disease mortality.  
 
Over 1 million women aged 50-74 were invited from the age/sex registers of 27 
participating primary care trusts in England, Wales and Northern Ireland. Women had 
to be postmenopausal at recruitment to be eligible for the trial. ‘Postmenopausal’ was 
defined as >12 months amenorrhoea following a natural or surgical menopause or >12 
months of HT commenced for menopausal symptoms.  Exclusion criteria were 
bilateral oophorectomy, previous ovarian malignancy, an active non-ovarian 
malignancy (excluding non melanoma skin cancer) and increased risk of familial 
ovarian cancer due to a family history. 
 
Those who accepted the invitation attended a recruitment appointment and completed 
a baseline questionnaire. This included a question on whether they were currently 
using HT and if yes, the duration of HT use.  In addition data was collected regarding 
hysterectomy and personal and family history of breast and ovarian cancer.  Women 
who fulfilled eligibility criteria were randomised by a customised data management 
system commissioned for the trial. The trial has ethical approval from the multicentre 
regional ethics committee (MREC 00/08/34) and local ethics committees, and all 
participants signed a consent form. 
 
Women were recruited into UKCTOCS between April 2001 and September 2005. The 
change in HT use over time was assessed by considering the proportion (%) of 
women randomised each month who were using HT when they attended for 
recruitment.  95% confidence intervals for the proportion estimate were used to 
validate any apparent trends.  Any differences in age distribution of the recruited 
population over time would distort the overall rate of HRT use. To adjust for this, the 
proportion of each age group (50-54, 55-59, 60-64 and 65 or over) using HT per 
month was multiplied by the overall proportion of participants in each age group and 
added over age group. This weighting method ensured that each age group had a 
constant (and appropriate) influence on overall HT use. Approximate confidence 
intervals for the percentage HT use per month were calculated using the normal 
approximation to the binomial distribution.  The adjusted estimate for proportion p 
and n=total recruited per month were used to estimate the respective mean and 
standard deviation. The extent of missing data was known to be very limited and so 
such records were discarded in the analysis without concern of bias. The HT trends 
were assessed with reference to the timing of the publication of the WHI interim 
results (July 2002), the MWS (August 2003) and advice on safety of HT use issued by 
the CSM (Dec 2003). 
 
Trends and differences in HT use were also explored between women stratified 
according to age (50-54, 55-59, 60-64 and 65 or over) and a personal history of breast 
cancer.  To formalise the relationship that may exist between the probability of HT 
use and the month of randomisation as well as membership of a particular subgroup, a 
binary logistic regression model was fitted to the whole dataset to quantify the nature 
of the variables’ dependencies 
 
Results 
 
Trial recruitment started in April 2001 and was completed in September 2005. During 
this period, 202,638 women were recruited and randomised. The median number of 
women recruited and randomised per month was 3,955 (mean 3,744.1). 
Randomisation numbers were <1,000 only in the first four months of the trial. 
 
All 202,638 women were >50 years of age, postmenopausal, with no history of 
ovarian malignancy or bilateral oophorectomy, or familial risk of ovarian cancer.  
There was no change over time in the proportion of recruited women with a personal 
history of breast cancer, number of relatives with breast or ovarian cancer or 
hysterectomy.  From April 2004 there was an increase in the number of women aged 
over 65 who joined the trial.  An adjustment for age was therefore made, as older 
women would be less likely to take HT. 453 women had incomplete data and were 
excluded from the remainder of the study. 
The actual percentages of women using HT at recruitment are shown in Table 1. 
Between April 2001 and June 2002, the average proportion of women using HT was 
28% with a slight initial upward trend.  This was followed by a clear downward trend 
in HT use starting in July 2002, coinciding with the publication of the WHI interim 
results.  From February to September 2005, the proportion of women using HT was 
between 10-11% (averaged 10.9%). The downward trend was confirmed in the age-
adjusted proportion (with 95% confidence intervals) of women randomised per month 
using HT at recruitment for the entire study period (Figure 1).  The p-value for the χ2 
test for independence between HT use and month recruited was highly significant 
(p=0.0001).  When binary logistic regression of the probability of HT use on month 
(considered as continuous and not categorical) was analysed, the passing of a month 
reduced the odds of a newly randomised woman taking HT by 3% (Table 2). 
 
There was reduction in HT use with increasing age (Figure 2).  The overall proportion 
using HT was 28.9% in 50-54 year women, 24.4% in 55-59, 16.6% in 60-64 and 8.7% 
in over 65 (Table 1).  Compared to women aged 50-54, the odds of using HT at 
recruitment was 19.0% lower in women aged 55-59; 46% lower in those aged 60-64 
and 74% lower in those aged over 65, given no change in the other variables (Table 
2). For all age groups, there was a decline in HT use from July 2002, although this 
decline was less pronounced for women over the age of 65.   
 
Among women with a past history of breast cancer (n=7635), overall HT use at 
recruitment was 2.9% (95% CI: 2.5%, 3.3 %) and significantly lower compared to 
women with no history of the disease (19.4%) (Table 1). Having had breast cancer 
reduced the odds of a woman using HT by 86% compared to woman who has not had 
breast cancer (Table 2). The percentage of randomised women per month taking HT 
in the subgroup with a past history of breast cancer exceeded 10% only once in 
January 2002.  It was at a lower level across all time points and there was a less 
discernable downward trend.   
 
When the trends were examined separately for each trial centre, the downward trends 
persisted. 
 
Discussion 
 
This report highlights the steady decline in HT use in postmenopausal women in UK 
in recent years.  The proportion of women aged 50-74 using HT at recruitment to the 
ovarian cancer screening trial, UKCTOCS, was 29% between April 2001 and June 
2002. However from July 2002 there was a steady decline in women using HT and by 
February 2005 to September 2005 only 10-11% of newly recruited women were using 
HT. 
 
Women aged 50-74 were randomly invited from 27 primary care trusts in England, 
Wales and Northern Ireland between 2001 and 2005 to participate in a 6 year 
randomised control trial of ovarian cancer screening.  This is in contrast to the more 
usual method of advertising the trial and allowing women to self refer. One fifth of 
the total population accepted the invitation and were then sent appointments to attend 
for trial recruitment (paper in preparation). However it is important to note that for 
2001, the overall rate of HT use (35%) at recruitment in postmenopausal women aged 
50-64 in our study was similar to the overall rate of HT use at recruitment of 33% in 
the MWS which recruited between 1996 and 2001.13 Women who volunteer to 
participate in research are usually more educated and informed.14-16 Our cohort 
consists of postmenopausal women in the UK who were willing and eligible to 
participate in a randomised control trial of ovarian cancer screening. Absolute rates of 
HT use may therefore not apply to the entire UK female population,13 but it is the 
relative differences between time points that is of particular interest. Given the large 
size of this national cohort and the pronounced decline in HT use in recruited women, 
the trend observed is probably representative of a general trend in the UK. The cohort 
itself is fairly homogenous as there was no change over time in the proportion of 
recruited women with a personal history of breast cancer, number of relatives with 
breast or ovarian cancer or hysterectomy. There was some variation in the proportion 
of women in various age groups over time and as this could impact on HT use, the 
rate of HT use was adjusted for age. The age-adjusted plots (Figure 1) confirmed the 
downward trend.  When the age groups were examined separately, the decline in HT 
use from July 2002 was present in all age groups. 
 
Similar downward trends have been reported from the USA17-19 and Europe20-22 in the 
period 2002-2003 immediately following publication of the trial results.  Studies 
reported a decline in HT prescribing in the USA from 14.6% in September 1999 to 
7.9% in June 2002 in women aged 40-80 years;19 The Netherlands from 10.7% in 
2000 to 8.7% in 2003 in women aged 45-69 years20 and in Hong Kong from 12.2% in 
the second half of 2000 to 4.5% by the first half of 2003 in women aged 50 or 
above.23 In an observational cohort study of postmenopausal US women aged 50-74 
undergoing mammography an 18% decline in HT use per quarter was documented 
during July 2002 and May 2003.18 Our report looks at the continuing trend beyond 
2003. The data shows a smaller rate of decline (3.2 % per month) in the UK, but one 
that continued to fall until February 2005 when it stabilized. An annual report on 
prescription costs for England by the Department of Health support these findings. In 
2001, there were 6.3 million HT prescriptions dispensed in England and by 2004, this 
had fallen to 3.8 million.24  
 
The timelines suggest that the decline is related to the publication of the WHI and 
MWS results.  In the USA, the dissemination of the WHI HT trial results had an 
immediate impact on the discontinuation of HT.17 Our data suggests that in the UK, 
the publication of the US study was followed by a gradual decline in HT use which 
fell more steeply after publication of the British MWS in August 2003.  The 
difference in impact of the two trials on HT use was also noted in the Netherlands 
with a modest decline in HT prescribing after the publication of the WHI study, 
followed by a dramatic fall in the prescribing of HT after release of results from the 
MWS.20 
 
Reports from small longitudinal cohort studies support the decline in HT use to be 
related to the WHI trial.25,26 The decline was, however less pronounced in Germany 
where in a survey of 8,380 women (mean age 56.1 years) only 25.7% reported 
stopping HT in response to the WHI results27 as opposed to 40% and 60% in the 
reports from New Zealand26 and USA25 respectively. In a recent paper from the UK 
the overall percentage of HRT users in a cohort of 1387 women aged 57 years 
declined from 31% in January 2002 to less than 26% by February 2003.28 
 
A number of factors may have contributed to this decline.  Media coverage of the 
WHI study had a significant influence on women’s use of HT.29 There was a 
misunderstanding about the magnitude of risks and benefits. The original publication 
and most of the ensuing publicity from WHI phrased the risks as a percent increase 
(or decrease) of the relative risk. For example, there was a 24% increased relative risk 
of breast cancer per year in the HT group. The general public, not understanding the 
concept of relative risk, interpreted this statement as a 24% chance of developing 
breast cancer each year on HT.30 An evaluation study of educational intervention on 
HT continuation rate in Slovenia confirmed that the main reason for discontinuing HT 
was fear of breast cancer, intensified by the media.31 A recent Cochrane review 
identified five studies that evaluated health care utilization before and after media 
coverage of specific events.32 Each found changes in utilization: favourable publicity 
was associated with higher use, unfavourable publicity with lower use.  The Cochrane 
review concluded that media reports played an important role in influencing the 
public's use of health care interventions.  Media coverage as distinct from the 
scientific importance of the work also plays an important role in transmitting 
knowledge to the scientific community.33 In addition, guidance circulated by most 
health care providers about the implications for prescribing HT probably contributed 
to the observed changes34 as did the advice given by physicians as women who 
continued to taking HT did so largely based on their physician’s advice.35 Interrelated 
with all of this, reduced promotion of HT by the pharmaceutical companies may have 
further played a role in the decline in prescriptions.36 
 
Since the WHI and MWS findings, use of complementary therapies seems to be on 
the increase37,38 although no alternative therapy has been cited in the literature or 
reported by the women surveyed to be as successful as oestrogen for symptom 
relief.39,40 Future patterns of hormone therapy use remain uncertain but will likely be 
shaped by multiple influences including professional and public attitudes toward risks 
and benefits and pharmaceutical marketing. The data about the pros and cons of HT 
use remain confusing but this report indicates that there probably has been a steady 
decline in HT use amongst postmenopausal women in the UK, similar to trends in the 
USA and Europe. 
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TABLE 1: PERCENTAGE OF WOMEN USING HRT BY MONTH AND BY 
SUB-GROUP 
 
 No of  
women 
Overall Age Group (years) Personal history 
of breast cancer 
50 - 54 55 -59 60 -64 65+ Yes No 
202,185*  39389 55497 46989 60310 7635 194550 
 Quarter  % using HT 
2 Q 2001 620 26.0 44.2 37.8 23.3 5.8 4.5 26.8 
3 Q 2001 3266 26.9 42.8 35.0 22.2 11.1 4.0 27.6 
4 Q 2001 6770 30.0 42.9 36.5 27.2 11.7 6.5 30.8 
1 Q 2002 8350 29.5 39.2 37.7 25.1 13.9 5.1 30.2 
2 Q 2002 11164 30.7 42.0 35.5 27.9 14.3 3.6 31.7 
3 Q 2002 13138 26.6 37.4 33.2 24.1 12.5 5.3 27.3 
4 Q 2002 14036 24.2 34.9 29.6 22.2 11.0 4.2 24.9 
1 Q 2003 15096 23.4 33.5 28.2 19.6 11.0 3.4 24.1 
2 Q 2003 14789 22.2 30.7 27.1 19.6 11.0 3.8 22.9 
3 Q 2003 14215 21.0 29.5 25.6 18.9 10.2 2.3 21.7 
4 Q 2003 13580 18.0 25.2 21.8 15.9 9.4 3.5 18.5 
1 Q 2004 15102 14.4 20.2 18.2 12.5 7.0 2.4 14.9 
2 Q 2004 11757 12.1 18.5 15.7 11.8 6.0 1.5 12.5 
3 Q 2004 11702 10.5 17.7 15.8 11.6 5.8 2.0 10.9 
4 Q 2004 10282 10.2 18.9 15.0 12.6 5.8 1.8 10.6 
1 Q 2005 12695 10.9 17.5 13.7 10.5 6.7 1.9 11.3 
2 Q 2005 13536 9.4 17.1 12.1 8.9 5.8 2.0 9.7 
3 Q 2005 12087 11.0 16.3 13.3 9.0 7.0 1.0 11.4 
Overall 202,185* 18.8 28.9 24.4 16.6 8.7 2.9 19.4 
   χ2 test: independence of (sub-)group and month 
p-value   <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.002 
 * Incomplete data in 453 women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2: RESULTS OF THE BINARY LOGISTIC REGRESSION  
 
Variable Group p-value  OR 
95% CI for OR 
Lower Upper 
Month  <0.001 0.97 0.97 0.97 
Breast Yes <0.001 0.14 0.12 0.16 
Age Group 
 
50-54  1.00   
55-59 <0.001 0.81 0.79 0.84 
60-64 <0.001 0.54 0.52 0.55 
65+ <0.001 0.26 0.25 0.27 
Constant  .065 0.97   
 
 
 
 
 
 
Figure legends 
  
Figure 1. Percentage of women randomised each month who were using HRT 
  
Figure 2. Proportion of women randomised per month in each age group using 
HRT 
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